Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal Infection

NCT00739934 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00739934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal Infection
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
October 31, 2009
Enrollment
40 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia, candidiasis